ReviewCancer metastasis reviews1993
EGF receptor in neoplasia and metastasis.
Review in Cancer metastasis reviews, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 292 citations in OpenAlex.
- Bioactive properties and clinical safety of a novel milk protein peptide.Nutrition journal · 2011Trial
- Review
- Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model.Frontiers in oncology · 2023Article
- Ras Signaling in Breast Cancer.Advances in experimental medicine and biology · 2021Article
- Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent.Molecular pharmaceutics · 2020Article
- Review
- The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.Molecular cancer · 2018Article
- EGFR-Signaling and Autophagy: How they Fit in the Cancer Landscape.Journal of adenocarcinoma · 2016Article
- Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-θ activation.Oncotarget · 2015Article
- Updates and knowledge gaps in cholesteatoma research.BioMed research international · 2015Review
- Epidermal growth factor receptor mutations in lung adenocarcinoma.Laboratory investigation; a journal of technical methods and pathology · 2014Review
- HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).Cellular signalling · 2014Article
- Molecular biology of adenoid cystic carcinoma.Head & neck · 2012Review
- Genetic and biochemical alterations in non-small cell lung cancer.Biochemistry research international · 2012Article
- Article
- Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.Journal of cellular physiology · 2011Article
- Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.The Journal of biological chemistry · 2011Article
- An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.The American journal of pathology · 2010Article
- [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma.Molecular imaging and biology · 2010Article
- Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating mammary epithelial acinar architecture.The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EGFR is a member of the tyrosine kinase family of cell surface receptors with a wide range of expression throughout development and in a variety of different cell types. The receptor can transmit signals to cells: i) upon interaction with ligands such as EGF, TGF alpha, amphiregulin or heparin binding EGF, ii) upon truncation or mutation of extracellular and/or intracellular domains, iii) upon amplification of a basal receptor activity (in the absence of ligand) through cooperation with other cellular signaling pathways or nuclear events (e.g. expression of v-erbA). The activated EGFR can exert pleiotropic functions on cells, depending on their tissue origin and state of differentiation. Under certain conditions it can also contribute to neoplasia and development of metastases. Such conditions can exist upon aberrant receptor/ligand expression and activation (e.g. in the wrong cell; at the wrong time; in the wrong amounts). Aberrant signalling can also occur through constitutive EGFR activation. Oncogenic potential of EGFR has been demonstrated in a wide range of experimental animals. EGFR is also implicated in human cancer, where it may contribute both to the initiation (glioblastoma) and progression (epithelial tumors) of the disease. EGFR may influence key steps in the processes of tumor invasion and dissemination. Involvement of EGFR in tumor spread may indicate a potential use of this receptor as a target for antimetastatic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.